Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 137
- Registration Number
- NCT02711137
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
- Conditions
- MMR-deficient TumorsSolid TumorsHead and Neck CancerPancreatic CancerColorectal Cancer (CRC)Lung CancerMelanomaEndometrial CancerBreast CancerRenal Cell Carcinoma (RCC)
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 159
- Registration Number
- NCT02646748
- Locations
- 🇺🇸
John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸Georgetown University Medical Center Lombardi CCC, Washington, District of Columbia, United States
🇺🇸The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision), Bethesda, Maryland, United States
Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 31
- Registration Number
- NCT02614612
Study of INCB053914 in Subjects With Advanced Malignancies
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 97
- Registration Number
- NCT02587598
- Locations
- 🇺🇸
Texas Oncology, Tyler, Texas, United States
🇺🇸Emory University-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸UC Davis comprehensive Cancer Center, Sacramento, California, United States
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT02559492
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
- Conditions
- Alopecia Areata
- Interventions
- Drug: Placebo Cream
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 90
- Registration Number
- NCT02553330
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
- Conditions
- Refractory Hodgkin LymphomaRecurrent Adult Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT02456675
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
- Conditions
- Solid Tumors and Hematologic Malignancy
- Interventions
- Drug: INCB054329 Monotherapy
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 69
- Registration Number
- NCT02431260
- Locations
- 🇺🇸
John Hopkins, Baltimore, Maryland, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
- Conditions
- UCMPNLung CancerSolid TumorGastric CancerUrothelial CancerEndometrial CancerMultiple MyelomaMyeloproliferative NeoplasmsBreast Cancer
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 201
- Registration Number
- NCT02393248
- Locations
- 🇺🇸
Ohio State University - Wexner Medical Center, Columbus, Ohio, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
- Conditions
- Solid Tumors and Hematologic MalignancyNSCLC (Non-small Cell Lung Carcinoma)
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT02355431